A two-country registry analysis associated benzodiazepine-related treatment with worse outcomes in schizoaffective disorder.
The study used Finnish and Swedish cohorts containing 7,655 and 7,525 patients, respectively. Within-individual analyses compared medication periods and tracked outcomes including hospitalization. Benzodiazepines and related drugs were associated with less favorable outcomes than several other pharmacotherapy patterns.
Within-person comparisons reduce some stable differences but do not eliminate changing symptom severity. Registers did not fully capture the clinical reasons for prescribing during a particular period. Worsening symptoms may prompt sedative treatment and also predict hospitalization.
In a treatment review, identify why and when the benzodiazepine was added. A registry association is not proof that the drug caused psychiatric deterioration. Contemporaneous symptoms, medication changes, adherence, and other treatment decisions are needed to explain a particular hospitalization.
Source reviewed: Long Term Real World Effectiveness of Pharmacotherapies for Schizoaffective Disorder (PMC8266596). This article summarizes the supplied paper; forensic applications above are interpretive analysis.
Related reading: Young-Child Nasal-Diazepam Study Separated Pharmacokinetics From Repeat-Dose Use; Valproate After Benzodiazepines: Why a Pooled Status-Epilepticus Response Rate Needs Context.